The obesity pipeline: current strategies in the development of anti-obesity drugs

Nat Rev Drug Discov. 2006 Nov;5(11):919-31. doi: 10.1038/nrd2136.


This review provides a summary of currently available pharmaceutical therapies for the treatment of obesity, along with an overview of the pipeline of products currently in development, and the key mechanisms on which the major development candidates are based. In particular, the recent increase in understanding of the role of gut peptides in energy homeostasis is highlighted as a promising source of potential future obesity therapies.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Obesity Agents / therapeutic use*
  • Central Nervous System / physiopathology
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Gastrointestinal Hormones / antagonists & inhibitors
  • Gastrointestinal Hormones / physiology
  • Humans
  • Lipase / antagonists & inhibitors
  • Obesity / drug therapy*
  • Obesity / physiopathology
  • Receptor, Cannabinoid, CB1 / drug effects


  • Anti-Obesity Agents
  • Enzyme Inhibitors
  • Gastrointestinal Hormones
  • Receptor, Cannabinoid, CB1
  • Lipase